hydroxychloroquine has been researched along with Inclusion Body Myopathy, Sporadic in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study we investigated COVID-19 vaccination-related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs)." | 1.72 | COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies. ( Agarwal, V; Aggarwal, R; Cavagna, L; Chatterjee, T; Chinoy, H; Day, J; Distler, O; Gaur, PS; Gheita, T; Gil-Vila, A; Gonzalez, RA; Gracia-Ramos, AE; Gupta, L; Joshi, M; Kardes, S; Kim, M; Knitza, J; Kuwana, M; Lilleker, JB; Makol, A; Milchert, M; Nikiphorou, E; Nune, A; Parodis, I; Ravichandran, N; Saavedra, MA; Salim, B; Selva-O'Callaghan, A; Sen, P; Shinjo, SK; Tan, AL; Velikova, T; Ziade, N, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gil-Vila, A | 1 |
| Ravichandran, N | 1 |
| Selva-O'Callaghan, A | 1 |
| Sen, P | 1 |
| Nune, A | 1 |
| Gaur, PS | 1 |
| Gonzalez, RA | 1 |
| Lilleker, JB | 1 |
| Joshi, M | 1 |
| Agarwal, V | 2 |
| Kardes, S | 1 |
| Kim, M | 1 |
| Day, J | 1 |
| Makol, A | 1 |
| Milchert, M | 1 |
| Gheita, T | 1 |
| Salim, B | 1 |
| Velikova, T | 1 |
| Gracia-Ramos, AE | 1 |
| Parodis, I | 1 |
| Nikiphorou, E | 1 |
| Tan, AL | 1 |
| Chatterjee, T | 1 |
| Cavagna, L | 1 |
| Saavedra, MA | 1 |
| Shinjo, SK | 1 |
| Ziade, N | 1 |
| Knitza, J | 1 |
| Kuwana, M | 1 |
| Distler, O | 1 |
| Chinoy, H | 1 |
| Aggarwal, R | 1 |
| Gupta, L | 1 |
| Limaye, VS | 1 |
| Cash, K | 1 |
| Smith, C | 1 |
| Koszyca, B | 1 |
| Patel, S | 1 |
| Greenberg, SA | 1 |
| Hissaria, P | 1 |
2 other studies available for hydroxychloroquine and Inclusion Body Myopathy, Sporadic
| Article | Year |
|---|---|
COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies.
Topics: Adult; Animals; Autoimmune Diseases; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Exanthema; Female; | 2022 |
Inclusion-body myositis and primary Sjögren syndrome: mechanisms for shared etiologies.
Topics: 5'-Nucleotidase; Adult; Autoantibodies; Azathioprine; CD8-Positive T-Lymphocytes; Female; Haplotypes | 2020 |